Joint Preservation Therapy Solutions in Knoxville, TN

CDC PLACES vs. JJ: two files, not one brochure

Joe Bradley will tell you the same thing he tells his own staff: epidemiology first, then MAC, then SKU. CDC PLACES (2023, crude) estimates 12.6% of adults in Knoxville have diagnosed diabetes — 0.6 points above the U.S. 12% figure. 12.9% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Then we pick joint preservation therapy against that mix.

Cash PRP and Medicare CTPs in the same hallway

• Adult arthritis here is 27.3% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 12.9% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Tennessee.
• Medicare wound-care biologics in Tennessee are paid under Palmetto GBA (JJ). CTP and skin-substitute LCDs are MAC-specific — a protocol that billed cleanly in another jurisdiction can stall here if documentation does not match JJ coverage articles.
• HCT/P 361 products must be minimally manipulated and used homologously. Tennessee medical boards and the FTC have both acted against regenerative advertising that implies stem-cell cures. Inventory choice and website copy have to match.

Uninsured mix and Medicare CTPs in the same building

JJ reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Knoxville is 12.6% or not. PLACES is planning data. The LCD is the claim.

Before the first joint preservation therapy shipment